Preliminary safety, pharmacokinetics (PK), and efficacy results from a phase I study of CS1003, an anti-programmed death-1 (PD-1) monoclonal antibody (mAb) in Chinese patients (pts) with advanced solid tumors or lymphoma

Preliminary Safety and Pharmacokinetics (PK) from a Phase I Study of CS1002, an Anti-Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody (mAb) in Patients with Advanced Solid Tumors

Preliminary safety, pharmacokinetics (PK) and pharmacodynamics (PD) from a Phase I study of CS1002, an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody (mAb) in patients (pts) with advanced solid tumors

一项关于抗PD-L1单克隆抗体CS1001的多中心、开放性、剂量扩展Ib期临床试验： CS1001联合顺铂和氟尿嘧啶(CF)治疗食管鳞癌患者的初步研究结果

一项关于PD-L1单克隆抗体CS1001的多中心、开放标签、剂量扩展的Ib期临床试验： CS1001单药治疗高度微卫星不稳定或错配修复缺失实体瘤患者的初步结果

Preliminary Results of a Phase 2 Clinical Study Evaluating the Anti‐Tumor Activity and Safety of CS1 in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma ( rr ‐ENKTL)

A phase III Clinical Trial of CS1001 As A Consolidation Therapy In Patients With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy (GEMSTONE 301)

Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).